FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083498943> ?p ?o ?g. }

• W3083498943 endingPage "CT150" @default.
• W3083498943 startingPage "CT150" @default.
• W3083498943 abstract "Abstract Background: OX40 is a costimulatory receptor transiently expressed on the surface of activated T cells and some innate immune cells (e.g. NK cells). OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in preclinical models, demonstrating increased efficacy when given in combination with a PD-1 inhibitor. GSK998 is a humanized IgG1 agonistic OX40 monoclonal antibody. Methods: ENGAGE-1 (NCT02528357) is a Phase 1 dose escalation study evaluating safety, PK, PD, and clinical activity of GSK998 (0.003-10 mg/kg IV Q3W) alone (Part 1) and in combination with pembrolizumab 200 mg IV Q3W (Part 2) in pts with previously treated advanced solid tumors: non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, renal cell carcinoma, melanoma (MEL), bladder cancer, soft tissue sarcoma (STS), triple-negative breast cancer, and MSI-high colorectal carcinoma. Dose escalation used a continuous reassessment method and 4-week DLT period. Results: A total of 138 pts were enrolled (45 Part 1, 96 Part 2; 3 crossed over from Part 1). Two DLTs occurred in Part 2 only (G3 non-malignant pleural effusion 0.03 mg/kg; G1 myocarditis 10 mg/kg); MTD was not established. Most common (≥10%) treatment-related AEs (mostly G1-2) were diarrhea, fatigue (Part 1) and fatigue, nausea (Part 2). GSK998 demonstrated target engagement in the periphery as evidenced by PK and receptor occupancy (RO); a dose of 0.3 mg/kg was the threshold for linear PK & peripheral RO saturation over the 3-wk dose interval and was selected for further clinical evaluation in MEL, STS, and NSCLC in Part 2 expansion. Clinical responses and SD ≥24 weeks were observed in both PD-1/L1 naïve and experienced pts: Part 1 (1 PR, 1 SD; both 0.3 mg/kg) and Part 2 (2 CR, 7 PR, 9 SD; 0.01-3 mg/kg); Part 2 clinical responses were not correlated with baseline tumor PD-L1 expression levels; including one MEL pt with PD-L1 TPS=0 who progressed on prior CTLA-4/PD-1 treatment and had a CR (&gt;18mo). Overall, peripheral and tumor expression of OX40 was low (&lt;2% total cells in tumor were OX40 +ve). MultiOmyxTM data from tumor biopsies suggested increased NK/decreased Treg involvement in some responders. Conclusions: GSK998 +/- pembrolizumab was well tolerated, with evidence of target engagement; monotherapy clinical activity was limited. While combination responses may not be significantly greater than expected for pembrolizumab alone, responses were observed in some PD-1/L1 experienced pts and some with low PD-L1 expression. Given the low OX40 expression observed and preclinical evidence that increased expression improves activity of OX40 agonism, ongoing clinical evaluation of GSK998 will assess whether concurrent immune-stimulation or immunogenic cell death impacts OX40 expression and increases the efficacy of this agent. Combinations with TLR4 and ICOS agonists and an anti-BCMA antibody-drug conjugate are ongoing. Citation Format: Sophie Postel-Vinay, Vincent K. Lam, Willeke Ros, Todd M. Bauer, Aaron R. Hansen, Daniel C. Cho, F. Stephen Hodi, Jan H.M. Schellens, Jennifer K. Litton, Sandrine Aspeslagh, Karen A. Autio, Frans L. Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M. Paul, Christoph M. Ahlers, Helen Zhou, Herbert Struemper, Shelby A. Gorman, Maura Watmuff, Kaitlin M. Yablonski, Niranjan Yanamandra, Michael J. Chisamore, Emmett V. Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S. Weber, John V. Heymach. A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT150." @default.
• W3083498943 created "2020-09-11" @default.
• W3083498943 creator A5000418012 @default.
• W3083498943 creator A5001241842 @default.
• W3083498943 creator A5002575629 @default.
• W3083498943 creator A5008444865 @default.
• W3083498943 creator A5011048678 @default.
• W3083498943 creator A5014113942 @default.
• W3083498943 creator A5014713051 @default.
• W3083498943 creator A5022267545 @default.
• W3083498943 creator A5027768129 @default.
• W3083498943 creator A5036068419 @default.
• W3083498943 creator A5036542143 @default.
• W3083498943 creator A5037195922 @default.
• W3083498943 creator A5038887077 @default.
• W3083498943 creator A5039160380 @default.
• W3083498943 creator A5042503296 @default.
• W3083498943 creator A5047177507 @default.
• W3083498943 creator A5048380048 @default.
• W3083498943 creator A5052046806 @default.
• W3083498943 creator A5059937355 @default.
• W3083498943 creator A5060793722 @default.
• W3083498943 creator A5063737641 @default.
• W3083498943 creator A5063752111 @default.
• W3083498943 creator A5065206480 @default.
• W3083498943 creator A5080783554 @default.
• W3083498943 creator A5081415754 @default.
• W3083498943 creator A5082495621 @default.
• W3083498943 creator A5083614176 @default.
• W3083498943 creator A5084967339 @default.
• W3083498943 creator A5086481435 @default.
• W3083498943 creator A5087234749 @default.
• W3083498943 creator A5088186975 @default.
• W3083498943 creator A5090778997 @default.
• W3083498943 date "2020-08-15" @default.
• W3083498943 modified "2023-10-01" @default.
• W3083498943 title "Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)" @default.
• W3083498943 doi "https://doi.org/10.1158/1538-7445.am2020-ct150" @default.
• W3083498943 hasPublicationYear "2020" @default.
• W3083498943 type Work @default.
• W3083498943 sameAs 3083498943 @default.
• W3083498943 citedByCount "16" @default.
• W3083498943 countsByYear W30834989432020 @default.
• W3083498943 countsByYear W30834989432021 @default.
• W3083498943 countsByYear W30834989432022 @default.
• W3083498943 countsByYear W30834989432023 @default.
• W3083498943 crossrefType "journal-article" @default.
• W3083498943 hasAuthorship W3083498943A5000418012 @default.
• W3083498943 hasAuthorship W3083498943A5001241842 @default.
• W3083498943 hasAuthorship W3083498943A5002575629 @default.
• W3083498943 hasAuthorship W3083498943A5008444865 @default.
• W3083498943 hasAuthorship W3083498943A5011048678 @default.
• W3083498943 hasAuthorship W3083498943A5014113942 @default.
• W3083498943 hasAuthorship W3083498943A5014713051 @default.
• W3083498943 hasAuthorship W3083498943A5022267545 @default.
• W3083498943 hasAuthorship W3083498943A5027768129 @default.
• W3083498943 hasAuthorship W3083498943A5036068419 @default.
• W3083498943 hasAuthorship W3083498943A5036542143 @default.
• W3083498943 hasAuthorship W3083498943A5037195922 @default.
• W3083498943 hasAuthorship W3083498943A5038887077 @default.
• W3083498943 hasAuthorship W3083498943A5039160380 @default.
• W3083498943 hasAuthorship W3083498943A5042503296 @default.
• W3083498943 hasAuthorship W3083498943A5047177507 @default.
• W3083498943 hasAuthorship W3083498943A5048380048 @default.
• W3083498943 hasAuthorship W3083498943A5052046806 @default.
• W3083498943 hasAuthorship W3083498943A5059937355 @default.
• W3083498943 hasAuthorship W3083498943A5060793722 @default.
• W3083498943 hasAuthorship W3083498943A5063737641 @default.
• W3083498943 hasAuthorship W3083498943A5063752111 @default.
• W3083498943 hasAuthorship W3083498943A5065206480 @default.
• W3083498943 hasAuthorship W3083498943A5080783554 @default.
• W3083498943 hasAuthorship W3083498943A5081415754 @default.
• W3083498943 hasAuthorship W3083498943A5082495621 @default.
• W3083498943 hasAuthorship W3083498943A5083614176 @default.
• W3083498943 hasAuthorship W3083498943A5084967339 @default.
• W3083498943 hasAuthorship W3083498943A5086481435 @default.
• W3083498943 hasAuthorship W3083498943A5087234749 @default.
• W3083498943 hasAuthorship W3083498943A5088186975 @default.
• W3083498943 hasAuthorship W3083498943A5090778997 @default.
• W3083498943 hasConcept C121608353 @default.
• W3083498943 hasConcept C126322002 @default.
• W3083498943 hasConcept C143998085 @default.
• W3083498943 hasConcept C2776256026 @default.
• W3083498943 hasConcept C2777472916 @default.
• W3083498943 hasConcept C2777658100 @default.
• W3083498943 hasConcept C2777701055 @default.
• W3083498943 hasConcept C2778570526 @default.
• W3083498943 hasConcept C2780057760 @default.
• W3083498943 hasConcept C502942594 @default.
• W3083498943 hasConcept C71924100 @default.
• W3083498943 hasConcept C90924648 @default.
• W3083498943 hasConceptScore W3083498943C121608353 @default.
• W3083498943 hasConceptScore W3083498943C126322002 @default.
• W3083498943 hasConceptScore W3083498943C143998085 @default.
• W3083498943 hasConceptScore W3083498943C2776256026 @default.
• W3083498943 hasConceptScore W3083498943C2777472916 @default.
• W3083498943 hasConceptScore W3083498943C2777658100 @default.
• W3083498943 hasConceptScore W3083498943C2777701055 @default.

• next